SEC Form 4 · accession 0001140361-17-023650
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
May 31, 2017
Accepted (ET)
Jun 2, 2017 · 5:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 31, 2017 | M | 7,423 | $17.33 | A | 240,987 | D | |
| Common StockF1,F2 | May 31, 2017 | S | 7,423 | $88.29 | D | 233,564 | D | |
| Common Stock | holding | — | — | — | 182,801 | I | Shares held by Jean-Jacques Bienaime Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F1,F3 | $17.33 | May 31, 2017 | M | 7,423 | D | Dec 7, 2007 | Jun 6, 2017 | Common Stock | 7,423 | 15,000 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on November 15, 2016.
- F2All shares sold at the same price.
- F3Reflects the number of stock options outstanding after the transaction from this specific stock option grant.